Ken Griffin Kinnate Biopharma Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $4,704 - $5,586	-2,100 Reduced 61.76%	1,300 $3,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $2.5 $963 - $2,250	900 Added 36.0%	3,400 $8,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $3,173 - $7,613	-2,300 Reduced 47.92%	2,500 $3,000
Q2 2023 Aug 14, 2023	SELL	$2.33 - $6.84 $3,262 - $9,576	-1,400 Reduced 22.58%	4,800 $14,000
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $20,760 - $47,880	6,000 Added 3000.0%	6,200 $38,000

Q4 2022 Feb 14, 2023	SELL	$5.26 - $12.19 $113,616 - $263,304	-21,600 Reduced 99.08%	200 $1,000
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $2,958 - $4,728	-300 Reduced 1.36%	21,800 $261,000

32.9M

94.7K

802K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.